oncgnostics GmbH
The oncgnostics GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.
oncgnostics GmbH is working according to ISO 13485 standards in research, development, production and management.
Our Topics
Recent Posts
Contact
oncgnostics GmbH
BioInstrumentezentrum Jena
Winzerlaer Str. 2
07745 Jena
Germany
Phone: +49 (0)3641 5548500
Email: contact[at]oncgnostics.com
Internet: www.oncgnostics.com
Sepsis: In which Patients does the Immune System Break Down?
Press ReleasesAs part of a new EU consortium, Oncgnostics GmbH is investigating diagnostic possibilities of immune collapse after sepsis. More than 140 people die every day in Germany of sepsis, commonly known as blood poisoning. Two thirds of them do not die from the out of control inflammatory reactions in the whole body, but rather from […]
Oncgnostics Expands Business Relations in Asia
Press ReleasesApproval for cervical cancer screening test in the Chinese market expected in early 2020 / First contacts in Japan Shanghai/Yokohama/Tokyo/Jena, 1 November 2019 –Our business partner in China, GeneoDx, is about to get approval to commercialise GynTect in the Chinese market. This issue was discussed at a business meeting with representatives from oncgnostics GmbH in […]
Early detection test GynTect® now available for Roche Diagnostics QPCR system
Press ReleasesJena, 20. February, 2019 – The test for early detection of cervical cancer GynTect® may now also be performed on the cobas Z480 analyzer, a widely used quantitative PCR (QPCR) system from Roche Diagnostics. This is now possible through an extension of the GynTect® CE IVD mark (CE mark for in vitro diagnostics). The biotech […]
Oncgnostics GmbH Presents New Clinical Data on GynTect® Precision Diagnostics at EUROGIN 2018
Press Releases, UncategorizedOncgnostics will discuss new clinical data with gynaecological key opinion leaders at EUROGIN 2018 SAN FRANCISCO, CA, USA, November 29, 2018 — Oncgnostics GmbH presents new clinical data on GynTect® Precision Diagnostics for triage of unclear cervical cancer screening tests. Oncgnostics GmbH, a Jena/Germany based company, has developed GynTect® for precision detection of cervical cancer. […]
Cervical Cancer Screening: oncgnostics Closes further Investment Round
Press ReleasesJena, October 17, 2018 – The Thuringian molecular diagnostics company oncgnostics, which quickly and successfully closed a 750,000 Euros crowd-investing round on Seedmatch early in 2018, now announces the closing of another similarly sized round. oncgnostics has developed the cervical cancer diagnostics test GynTect®, and a private investor circle now invests together with the current […]
Oncgnostics GmbH retains Biotech Alliances International Inc. to support global partnering and distribution strategy.
Press Releases2018-10-02 San Francisco/Jena, Germany: Biotech Alliances International Inc., a Silicon Valley-based healthcare-focused investment bank, announced today that it will serve as the lead investment banker to Oncgnostics globalisation and partnering strategy. Early detection of cervical cancer is critical for patient’s health and survival. Current diagnostic methods are inefficient and fail to detect 50% of the […]
Test for Uterine Cancer in Portugal: Biotech Firm oncgnostics Grants Exclusive Licence for Cancer Screening Test
Press Releases, UncategorizedLisbon/Jena, April 16th 2018 – Speculum S.A. is the exclusive licence partner of oncgnostics GmbH for the screening test GynTect® in Portugal. The test is designed to further specify abnormal results in screening examinations and to help determine the best treatment approach. In January, the biotech firm oncgnostics GmbH from Jena (Germany), concluded an […]
Reliable test for cervical cancer triage now available in Slovakia and the Czech Republic: Biotech company oncgnostics concludes an exclusive partnership with the MEDIREX group
Press Releases, UncategorizedJena, January 31th 2018 – oncgnostics GmbH partners with the MEDIREX Group. MEDIREX thus holds the exclusive rights for marketing the test for early and reliable detection of cervical cancer, GynTect®, for Slovakia and the Czech Republic. Following their successful crowd-funding via the platform Seedmatch, oncgnostics GmbH takes the next step for internationalization: the […]
GynTect soon available in China: – oncgnostics grants exclusive license for GynTect to the Chinese SINOPHARM subsidiary CJMT – approval for the Chinese market planned
Press Releases, UncategorizedJena, April 5th, 2017: The Chinese pharma company Changchun Jienuo Medical Technology (CJMT), a subsidiary of the Chinese state-owned SINOPHARM Group (www.sinopharm.com/en), has purchased an exclusive license from oncgnostics (www.oncgnostics.com) for marketing GynTect® in China, Hongkong and Macao. The contract comprising four milestones rules the approval of GynTect® at the Chinese Food and Drug Agency […]
oncgnostics presents extended version of its cervical cancer diagnostics test GynTect at MEDICA
Press Releases, UncategorizedJena, November 9th, 2016 – The biotech company oncgnostics (www.oncgnostics.com) will present its new version of the triage test GynTect – a test for the fast and reliable detection of cervical cancer – at the world-leading trade fair Medica. Between 14th and 17th of November 2016 the epigenetics experts will explain the advantages of the […]